Neuroendocrine alterations in the somatotrophic axis in chronic renal failure.
Both secretion and metabolic clearance of GH in health and disease are subject to regulation by an array of metabolic, nutritional, physical activity, age, and body composition cues. Moreover, both GH and its mediators (e.g. IGF-I) are bound in plasma by one or more high-affinity binding proteins. Accordingly, carefully designed clinical and basic investigations are required to examine and clarify the diverse alterations in the dynamics of the somatotrophic axis that accompany the syndrome of CRF with its attendant attenuation of normal anabolism, growth and development.
Veldhuis
J D
JD
Interdisciplinary Graduate Biophysics Program, University of Virginia Health Sciences Center, Charlottesville.
Johnson
M L
ML
Wilkowski
M J
MJ
Iranmanesh
A
A
Bolton
W K
WK
D002352:Carrier Proteins / Q000378:metabolism; D002648:Child; D005260:Female; D013006:Growth Hormone / Q000172:deficiency / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000172:deficiency / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology* / Q000628:therapy; D008297:Male; D009490:Neurosecretory Systems / Q000378:metabolism / Q000503:physiopathology*; D014882:Water-Electrolyte Balance
D002352:Carrier Proteins; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone